Abstract
MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Current Pharmaceutical Design
Title:Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies
Volume: 23 Issue: 39
Author(s): Xiaohong Du, Jitai Zhang, Juping Wang*, Xiaoming Lin*Feng Ding*
Affiliation:
- Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Collaborative and Creative Center of Molecular Pathology and Personalized Medicine, Department of Pathology, Shantou University Medical College, Shantou, Guangdong 515041,China
- Department of Thoracic Surgery, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000,China
- Department of Physiology, School of Basic Medical Sciences, Wenzhou Medical University, Chashan Campus, Wenzhou, Zhejiang 325035,China
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Abstract: MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Export Options
About this article
Cite this article as:
Du Xiaohong , Zhang Jitai , Wang Juping *, Lin Xiaoming *, Ding Feng *, Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714150118
DOI https://dx.doi.org/10.2174/1381612823666170714150118 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets The ModifiedGlasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature
Reviews on Recent Clinical Trials The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design FoxQ1 is a Novel Molecular Target for Pancreatic Cancer and is Associated with Poor Prognosis
Current Molecular Medicine Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Editorial (Hot Topic: Vitamin D and Cancer: Current Evidence and Future Perspective)
Anti-Cancer Agents in Medicinal Chemistry Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA
Anti-Cancer Agents in Medicinal Chemistry Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer
Current Cancer Therapy Reviews An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design NMR-based Metabolite Profiling of Pancreatic Cancer
Current Metabolomics Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine